The antidepressant efficacy of reboxetine in patients with severe depression

Journal of Clinical Psychopharmacology

Volumn 23, Issue 1, 2003, Pages 45-50

  Montgomery, Stuart ^a,e   Ferguson, James M ^b   Schwartz, Gerri E ^c,d  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF UTAH   (United States)

^c PFIZER INC   (United States)

^d College of Physicians and Surgeons ^*  (United States)

^e NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; REBOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 0037309541     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200302000-00008     Document Type: Article

References (25)

1. Delgado PL and Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry 2000;6(Suppl 1):5-12.
2. Johnston TG, Kelley CB, Stevenson MR, et al. Plasma norepinephrine and prediction of outcome in major depressive disorder. Biol Psychiatry 1999;46:1253-58.
3. Montgomery SA. Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 1997;7(Suppl 1):S3-S9.
4. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-49.
5. Amsterdam JD. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 1998; 12(Suppl B):S99-S111.
6. Kasper S, Heiden A. Do SSRIs differ in their antidepressant efficacy? Hum Psychopharmacol 1995;10:S163-S172.
7. Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 1999;60(Suppl 4):14-21.
8. Boyce P and Judd F. The place for the tricyclic antidepressants in the treatment of depression. Aust N Z J Psychiatry 1999;33:323-327.
9. Kent JM. SNaRIs, NaSSAs and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-18.
10. Montgomery SA. Predicting response: noradrenaline reuptake inhibition. Int Clin Psychopharmacol 1999;14(Suppl 1):S21-S26.
11. Montgomery SA, Lecrubier Y. ECNP Consensus Meeting September 20, 1996, Amsterdam. Is severe depression a separate indication? Eur Neuropsychopharmacol 1999:9;259-64.
12. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 1998;13:S29-S39.
13. Berzewski H, Van Moffaert M, Gagiano C. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997;7(Suppl 1):S37-S47.
14. Andreoli V, Caillard V, Deo RS, et al. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002;22:393-9.
15. Katona C, Bercoff E, Chiu E, et al. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorder: a double-blind randomised trial. J Affect Disord 1999;55:203-13.
16. Massana J, Moller H-J, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80.
17. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34.
18. Versiani M, Mehilane L, Gaszner P, et al. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999;60:400-6.
19. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11::S9-S15.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
21. Guy, W. ECDEU Assessment Manual for Psychopharmacology. Revised 1976. Rockville, Md: U.S. Department of Health, Education and Welfare; 1976. Publication No. (ADM) 76-338.
22. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-8.
23. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized with depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9(3):139-43.
24. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe depressive disorder. J Clin Psychiatry 1998;59: 306-12.
25. Lopez-Ibor J, Guelfi JD, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996;11:41-6.